-
Mashup Score: 3
For the general population, lower cholesterol, particularly lower LDL cholesterol, is good news for cardiovascular risk. Christina Charles-Schoeman, MD, MS, and Jorge Plutzky, MD, explained its impact on patients with rheumatoid arthritis and other rheumatic diseases.
Source: ACR Convergence TodayCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0170-year-old report promoting racial discrimination in healthcare continues to negatively affect outcomes - ACR Convergence Today - 2 year(s) ago
Ashira D. Blazer, MD, discussed the origins and realities of modern-day racism and racial disparities in healthcare, including how to navigate negative behaviors such as microaggression and gaslighting.
Source: ACR Convergence TodayCategories: Latest Headlines, RheumatologyTweet-
ICYMI at #ACR21: @ashira_md discussed the origins & realities of racism & racial disparities in healthcare → https://t.co/R5QyzHWNWU https://t.co/9aoppLqihR
-
-
Mashup Score: 4ACR Convergence - 2 year(s) ago
Don’t miss rheumatology’s premier scientific meeting, ACR Convergence, for anyone involved in research or the delivery of rheumatologic care or services.
Source: www.rheumatology.orgCategories: Latest Headlines, RheumatologyTweet-
Available to all ACR Convergence 2021 All-Access Pass participants, Debriefs & Poster Tours highlight the groundbreaking science presented during #ACR21 abstract sessions. Don’t miss #interprofessional team tomorrow, Friday, Jan. 7, 12 p.m. ET. Details → https://t.co/TBLnNeiEax https://t.co/AE1SjyLv3l
-
-
Mashup Score: 1ACR Convergence Registration - 2 year(s) ago
See information about ACR Convergence registration fees and timelines, official housing, and group registration.
Source: www.rheumatology.orgCategories: Latest Headlines, RheumatologyTweet-
Catch the best science from #ACR21! Didn’t get a chance to join us in November? Purchase an On-Demand All-Access Pass & view sessions until March 11 → https://t.co/3oPN9VpdOm https://t.co/xwz7YL5tCT
-
-
Mashup Score: 2ACR Convergence 2021 - 2 year(s) ago
The ORAL Surveillance study is a phase 4, open-label, safety trial designed to assess whether adverse effects of the Janus kinase (JAK) inhibitor tofacitinib were comparable (ie, non-inferior) to TNF inhibitors with regard to major adverse cardiovascular events (MACE) and malignancies in high-risk patients with rheumatoid arthritis. Patients with moderate-to-severe rheumatoid arthritis…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
In the January issue—read our highlights of #ACR21 https://t.co/UUk1DiWuC5 https://t.co/kaTAJUdwst
-
-
Mashup Score: 2First Impressions — Should We Include Race or Ethnicity at the Beginning of Clinical Case Presentations? | NEJM - 2 year(s) ago
Perspective from The New England Journal of Medicine — First Impressions — Should We Include Race or Ethnicity at the Beginning of Clinical Case Presentations?
Source: New England Journal of MedicineCategories: Latest Headlines, RheumatologyTweet-
We had this exact same vigorous discussion on the last day of the #SLE community hub @ACRheum #ACR21 with @ashira_md, @karen_kc123 & many others. TL;DR race is not a surrogate of a biologic foundation, rather a dynamic social construct. https://t.co/6wFbz25UoR
-
-
Mashup Score: 0ACR Convergence 2021 - 2 year(s) ago
ACR Convergence is the world’s premier virtual rheumatology experience where rheumatology can collaborate, celebrate, innovate, & learn. Join us online November 5 – 9.
Source: meet.acrconvergence.orgCategories: Latest Headlines, RheumatologyTweet-
ACR Convergence 2021 attendees – Catch up on sessions you missed during #ACR21 or rewatch your favorites. Your on-demand access to the session recordings, Poster Hall, Community Hubs & ShowRheum continues through March 11, 2022. Watch → https://t.co/l3P55JOSDZ https://t.co/m9F7SyuSXn
-
-
Mashup Score: 1
Therapeutic drug monitoring, in which serum levels are regularly checked to adjust dose and intervals, is more effective at controlling disease than standard therapy with infliximab, according to data presented at ACR Convergence 2021.“Several observational studies have revealed a considerable inter-individual variation in serum drug levels for infliximab and other TNF inhibitors,
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
Published today in JAMA: Data first presented at #ACR21 and reported in @HealioRheum that therapeutic drug monitoring is more effective at controlling disease than standard therapy with #infliximab https://t.co/G3pCjqsNPi
-
-
Mashup Score: 0Challenges to rheumatology practices won’t end with the COVID-19 pandemic - ACR Convergence Today - 2 year(s) ago
NORM President Nancy Ellis, BA, MBA, MHA, shared member survey results in an update on the operational challenges of delivering patient care as practice managers look beyond the pandemic.
Source: ACR Convergence TodayCategories: Latest Headlines, RheumatologyTweet-
ICYMI at #ACR21: @NORMGrp reviewed how #rheum practices have responded to #COVID19 & previewed potential reimbursement changes → https://t.co/cMRo0n7uc5 https://t.co/hEC1pFZVAy
-
-
Mashup Score: 2Researchers identify host factors that contribute to COVID-19 severity - ACR Convergence Today - 2 year(s) ago
Dusan Bogunovic, PhD, described the latest immune profile findings in MIS-C and Qian Zhang, MD, discussed type I interferon response in severe COVID-19 during a basic science session at ACR Convergence.
Source: ACR Convergence TodayCategories: Latest Headlines, RheumatologyTweet-
ICYMI at #ACR21: @bogunoviclab & @tutu_zq highlighted some of the host factors that result in highly variable responses to #COVID19 → https://t.co/IbJgzxP7Iw https://t.co/2SSJeH4UUN
-
ICYMI at #ACR21: A look at cholesterol levels & cardiovascular disease risk in patients with #rheum diseases → https://t.co/IwKnnmj7No https://t.co/xP1uy6S2KR